Dendreon
PROVENGE
Manufacturer:
Dendreon
Name:
PROVENGE
HCPCS Code Descriptor:
Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion
Category:
Q Code
HCPCS:
Q2043
NDC(s):
30237-8900-06
Primary Type:
Oncology
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
PROVENGE is an Oncology drug manufactured by Dendreon and administered via the Intravenous route of administration. The Q Code: Q2043 is aligned to the drug PROVENGE.